血小板生成素受体激动剂联合利妥昔单抗治疗复发/难治性ITP:多中心真实世界研究
多中心回顾性纳入161例复发/难治性免疫性血小板减少症(ITP)患者,接受TPO-RA联合利妥昔单抗治疗,最佳总缓解率83%,中位随访22个月30%达无治疗缓解,不良事件16%且多为轻中度。女性、年龄<45岁、病程<24个月及抗核抗体阳性为无治疗缓解独立预测因素。
要点
- TPO-RA联合利妥昔单抗治疗复发/难治性ITP最佳总缓解率83%,完全缓解43%。
- 中位随访22个月,30%患者达无治疗缓解,不良事件16%且无治疗相关死亡。
- 女性、年龄<45岁、病程<24个月、抗核抗体阳性者无治疗缓解概率更高。
核心结论
- TPO-RA联合利妥昔单抗对复发/难治性ITP有效且耐受性良好,部分患者恢复对既往无效TPO-RA的敏感性。
研究设计与样本
- 回顾性多中心真实世界研究,纳入中国六家中心161例复发/难治性ITP患者,接受TPO-RA联合利妥昔单抗治疗。
主要发现
- 最佳总缓解率83%,完全缓解43%,部分缓解40%。
- 中位随访22个月,30%患者达无治疗缓解。
- 利妥昔单抗使29%对既往TPO-RA原发耐药患者和40%继发耐药患者恢复血小板应答。
- 不良事件发生率16%,多为轻中度,无治疗相关死亡。
关键数值与推荐
- 多因素分析:女性、年龄<45岁、病程<24个月(OR 10.70)、抗核抗体阳性(OR 4.36)为无治疗缓解独立预测因素。
- 既往TPO-RA暴露(OR 0.24)和低剂量利妥昔单抗(OR 0.33)与较低的无治疗缓解几率相关。
临床怎么用
- 对复发/难治性ITP,尤其女性、年龄<45岁、病程<24个月及抗核抗体阳性患者,可考虑TPO-RA联合利妥昔单抗。
- 对既往TPO-RA耐药患者,联合利妥昔单抗可能恢复部分患者对TPO-RA的敏感性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The management of relapsed/refractory immune thrombocytopenia (ITP) remains challenging, and real-world evidence on the combination of thrombopoietin receptor agonists (TPO-RAs) and rituximab is limited. OBJECTIVES: To evaluate the efficacy, safety, and predictors of response to this combination regimen in a large multicenter cohort. METHODS: This retrospective study included 161 patients with relapsed/refractory ITP from six Chinese centers who received TPO-RAs combined with rituximab. Treatment response, durability, safety, and predictors of treatment-free remission (TFR) were analyzed. RESULTS: Patients were heavily pretreated, with a median of four prior therapies and 93% refractory to previous treatment. The best overall response rate was 83%, with 43% achieving complete response and 40% partial response. After a median follow-up of 22 months, 30% of patients attained TFR. Notably, rituximab restored platelet response in 29% of patients primarily refractory to their prior TPO-RA and in 40% of those with secondary resistance. Multivariate analysis identified female sex, age <45 years, disease duration <24 months (OR 10.70), and positive antinuclear antibody (OR 4.36) as independent predictors of TFR, while prior TPO-RA exposure (OR 0.24) and low-dose rituximab (OR 0.33) were associated with lower TFR odds. Adverse events occurred in 16% of patients and were mostly mild to moderate, with no treatment-related deaths. CONCLUSIONS: Combination therapy with TPO-RAs and rituximab is effective and well tolerated in relapsed/refractory ITP, particularly in female patients aged <45 years with disease duration <24 months and in anti-ANA-positive patients. In a subset of patients, the combination restored sensitivity to previously ineffective TPO-RAs.
引用
- Tian H, Song X, Huang Y, et al. Combination of Thrombopoietin Receptor Agonists and Rituximab in Relapsed/Refractory Immune Thrombocytopenia: A Multicenter Real-World Study. J Thromb Haemost. 2026. PMID: 42933655. doi:10.1016/j.jtha.2026.10.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。